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Design and In Vitro Interference Test of Microwave
Noninvasive Blood Glucose Monitoring Sensor
Heungjae Choi, Member, IEEE, Jack Naylon, Steve Luzio, Jan Beutler,
James Birchall, Chris Martin, and Adrian Porch
Abstract—A design of a microwave noninvasive continuous
blood glucose monitoring sensor and its interference test results
are presented. The novelty of the proposed sensor is that it com-
prises two spatially separated split-ring resonators, where one
interacts with the change in glucose level of a sample under test
while the other ring is used as a reference. The reference ring
has a slightly different resonant frequency and is desensitized
to the sample owing to its location, thus allowing changes in
temperature to be calibrated out. From an oral glucose tolerance
test with two additional commercially available sensors (blood
strip and continuous glucose monitor) in parallel, we obtained
encouraging performance for our sensor comparable with those
of the commercial sensors. The effects of endogenous interferents
common to all subjects, i.e., common sugars, vitamins (ascorbic
acid), and metabolites (uric acid) have also been investigated by
using a large Franz cell assembly. From the interference test,
it is shown that the change in sensor response is dominated by
changes in glucose level for concentrations relevant to blood, and
the effects of interferents are negligible in comparison.
Index Terms—Biomedical sensors, dielectric measurements,
emerging application for RF/microwaves, material characteriza-
tion, microwave sensors.
I. INTRODUCTION
D IABETES IS a huge worldwide problem whose preva-lence is rapidly increasing. The number of people with di-
abetes is estimated to increase to 5 million in 2025 in the U.K.
only [1], and 366 million in 2030 worldwide [2]. Due to lim-
ited capabilities of public healthcare systems, it is necessary for
people with diabetes to be able to self-monitor their own blood
glucose levels. Blood glucose meters using blood strips with
ﬁnger pricking lancets are the most common method widely
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available because of their reasonably high accuracy and preci-
sion, high convenience, low cost, and their ability to provide
real-time plasma glucose levels on demand. However, ﬁngers
can become painful if regular testing is needed (as in people
with type I diabetes) and this type of testing can be more of a
problem for some patient groups, e.g., infants.
Over the last few decades, a variety of minimally or non-
invasive blood glucose monitor (NIBGM) devices based on a
wide range of interesting technologies have been introduced
[3]–[5]. To name a few of the most recent technologies, a
transdermal glucose sensor using ultrasound [6], a small im-
plantable ﬂuorescent technology-based sensor combined with
a body-worn data transmitter [7], a watch-type sensor [8],
an ultrasound-based ear-clip type noninvasive multi-sensor
for discrete measurement [9], contact-lens-type noninvasive
sensor [10], occlusion spectroscopy-based sensor measuring
blood ﬂow [11], and electrochemical subcutaneous continuous
monitoring sensors [12] have been developed, pursuing their
way towards obtaining necessary approval to enter the market.
In the RF and microwave area, the near-ﬁeld monitoring tech-
nique has been widely used for its noninvasive characteristic.
A broadband coplanar waveguide sensor with the combination
of microﬂuidic system [13], an open-ended spiral-shaped
microstrip transmission line sensor [14], microstrip patch/slot
antenna-based sensor [15]–[17], and millimeter-wave wave-
guide transmission measurement system [18] have been
reported using microwave technique. The basis of these is that
the complex dielectric constant changes with the presence and
ﬂuctuation of blood glucose concentration in the water/glucose
system [19], [20].
We have chosen microwaves as the technological platform
for our NIBGM sensor since resonance-based microwave sen-
sors have been used extensively in the precise dielectric charac-
terization of organic and inorganic materials in minimally inva-
sive or noninvasive ways [21]–[25]. Furthermore, microwaves
around 1 GHz penetrate the body by a few centimeters, and
in the NIBGM application microwave power levels of only 1
mW are needed, so they are a nonionizing low-power exposure.
Therefore, we believe that the microwave method is precise,
safe, and fast, providing continuous readings at sub-second in-
tervals if required.
In a microwave resonating structure, it is almost impossible
to monitor the temperature within the resonator by conventional
means because the presence of temperature measuring compo-
nents (for example, a thermistor and its wires) would affect the
resonance. The measured temperature is also the ambient tem-
perature rather than the temperature of the resonating element
This work is licensed under a Creative Commons Attribution 3.0 License. For more information, see http://creativecommons.org/licenses/by/3.0/
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itself, which, in this case, is the ring resonator. The novelty of
the proposed sensor lies in the fact that it has a reference ring
in parallel with the sensing ring. The reference ring is placed:
1) far enough from the human skin so it is not affected by a prop-
erty change of the human body in the immediate vicinity of the
sensor (in this case, its effective dielectric constant) and 2) far
enough from the sensing ring so they are not mutually coupled to
each other so that the reference ring is not affected by the prop-
erty change. However, both rings are made of the same mate-
rial (silver-coated copper wire), have the same gap distance, and
share the same polytetraﬂuoroethylene (PTFE) pillar as a sup-
porting structure. Therefore, when the temperature of the whole
sensor changes, both rings will exhibit similar temperature de-
pendences. Therefore, we are able to monitor the temperature of
the proposed sensor by monitoring the resonant frequency and
3-dB bandwidth of the reference ring without having any kind
of dedicated temperature sensor. The pre-characterized temper-
ature dependence of the sensing ring is then used to calibrate
out the temperature-dependent effects from the measurement.
The design criteria and equivalent circuit model of the pro-
posed sensor is given in [27]. The added value of this paper is
that more practical design aspects are discussed including 3-D
sensor and body modeling, and the effects of endogenous inter-
ferents common to all subjects, e.g., common sugars, vitamins
(ascorbic acid), and metabolites (uric acid) are investigated by
using a large Franz cell assembly. In Section II, we will discuss
the design of ourmicrowave NIBGM sensor using split-ring res-
onators by focusing on the practical design aspects. The exper-
imental setup and results of the interference tests are presented
in detail in Section III.
II. SENSOR DESIGN
A. Double Split-Ring Resonators
Since its introduction, the split-ring resonator has been used
as one of the main tools of material characterization [21]–[26].
Its key beneﬁt is that it can easily be designed for the size and
shape of a given sample rather than having to shape the sample
to ﬁt into the existing resonator, for example, as in a cavity res-
onator. Especially when we consider noninvasive continuous
monitoring of the human body, any such sample shaping, of
course, is difﬁcult. In this work, we have chosen a lumped-ele-
ment split-ring resonator because it has stronger leakage of its
electric ﬁeld (E-ﬁeld) from the gap area. A relatively low oper-
ating frequency, around 1.4 GHz, is chosen to allow for greater
penetration of E-ﬁeld and greater surface area of interaction.
Fig. 1 shows the 3-D model of the proposed sensor based on
a pair of lumped-element split-ring resonators. The ring is made
from silver-coated copper wire of 1.5-mm diameter. Each ring
has a gap distance of 1 mm so each forms a lumped-element
resonator. The resonant frequency can be estimated from
the following equation in general form [21]:
(1)
where is the velocity of light, is the internal radius of the
ring, is the gap width, is the gap distance, is the shield
Fig. 1. 3-D structure of the proposed sensor based on discrete double split-ring
resonators, after [27]. The skin side of the sensor is pointing downwards.
Fig. 2. Cross-sectional top view (left) and side view (right) of the proposed
sensor.
radius, is the height of the resonator, is the equivalent
width extension of the gap due to the gap electric leakage ﬁelds,
and is the equivalent length extension due to the magnetic
leakage ﬁelds. When the resonator is made of a single core wire,
as illustrated in Fig. 2, and . A ring with
an internal radius of 13 mm with 1-mm gap supported by a
solid PTFE pillar gives a resonant frequency of approximately
1.4 GHz.
A cylindrical aluminium shield is used with one side open
to conﬁne the electromagnetic (EM) ﬁeld and focus it towards
the human body (on the open side). The radius of the shield is
16 mm. A hat-shaped supporting pillar made of low-loss PTFE
with a radius of 13 mm is used to hold the rings in position.
The EM ﬁelds of the split ring spill out of the open side of the
aluminium shield, i.e., the side that will be ﬁxed to the body;
this is the bottom surface, as shown in Fig. 2.
The split-ring resonator can be coupled by both inductive and
capacitive coupling techniques. To minimize the possible im-
balance in the coupling strength between two ports, we have
chosen the capacitive probe coupling rather than inductive loop
coupling. It is also easier to fabricate a uniform probe, which is
an extension of the inner conductor of the coaxial cable, than
equivalent loops. To equally couple to two concentric rings that
are vertically separated, a small patch is added at the end of the
probe to increase the coupling strength. The antenna probe cou-
ples to the E-ﬁeld in the proximity of the gap.
The two rings are wound from 1.5-mm-diameter silver-
coated copper wire, with resonant frequencies offset from each
other, by about 250 MHz in this case. In the current design,
the resonant frequency of the sensing ring is lower than the
reference ring since its frequency is reduced the most due to
the dielectric loading of the body. The sensing ring is located
closer to the body, while the reference ring is further away
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Fig. 3. Measurement and post-simulation results of the equivalent circuit
model given in [27] when the sensor is loaded with air and body. The circuit
values in the simulation used to ﬁt the measured results are as follows:
H (air) and H (body), fF (air) and fF
(body), , (air) and 100 (body), H,
fF (air) and fF (body), nH, pF.
Attenuators of 7.5 dB (air) and 9.5 dB (body) are added on each side of the
ports to emulate coupling losses.
from the body. The key idea is to place the reference ring far
enough from the body so that the EM ﬁeld from the reference
ring has minimal interaction with the body, while the EM ﬁeld
from the sensing ring interacts strongly. Since they have the
same temperature expansion coefﬁcient, the reference ring will
provide us the change in property only due to the temperature,
which can be used for temperature calibration of the measured
data from the sensing ring.
To visualize the sensing and reference ring operations, a
simple equivalent-circuit model is presented in [27]. Mea-
surement and simulation results are shown in Fig. 3 by using
Advanced Design System (ADS) 2011 by Keysight Tech-
nology. Measurement shows the transmission characteristic
when the sensor is in the air and on the body. In simulation, the
change in loading condition when the sensor is on the body is
emulated equivalently by varying the gap capacitance ,
the quality factor , and inductance of the sensing
ring. The distance between the rings can be determined in such
a way that: 1) the reference ring is not affected by any change
in human body and 2) both rings do not mutually couple to
each other, avoiding shifts in resonance frequencies and distor-
tion of the measurement characteristics. The vertical distance
between the rings is 8 mm in the proposed design. As shown
in Fig. 3, the constancy of resonant peaks of the reference
ring demonstrates that it is almost unaffected by the dielectric
changes in the human body and also by any characteristic
change in the sensing ring. The measured frequency shift of the
reference peak is 600 kHz, which is a fractional frequency shift
of 0.034% at 1.74 GHz. The measured of the sensing peak is
about 800 when in the air, and 80 when on the body.
B. 3-D Sensor and Body Modeling
To further investigate how the EM ﬁeld produced from the
ring resonator penetrates into the human body through different
Fig. 4. 3-D abdominal cross-section model with the proposed sensor.
Fig. 5. Simulated normalized E-ﬁeld distribution of 1 V/m at 1.433 GHz,
showing penetration depth through skin, fat, and muscle layers when excited
by a microwave input power level of 1 mW.
TABLE I
DIELECTRIC PROPERTIES OF EACH LAYER
layers with different dielectric properties, a simple 3-D abdom-
inal cross-section model is created in COMSOL Multiphysics
v4.4, as shown in Fig. 4. The model consists of skin, fat, muscle,
internal organs, and vertebrae (speciﬁcally, lumbar vertebrae)
bone. The thicknesses of the skin, fat, muscle layer are 3, 7,
and 35 mm, respectively, and the radius of vertebrate is 30 mm.
Internal organs are assumed to ﬁll the region between the ver-
tebrae and muscle layer with a minimum thickness of 25 mm.
The overall dimensions of the model are 400 mm 200 mm
60 mm, based on a healthy male adult. The dielectric properties
of each layer measured at 1.4 GHz are listed in Table I, obtained
from [14]. From a series of iterations, we found that only a small
portion of the model where the sensor is located has direct effect
on the EM-ﬁeld distribution. Therefore we decided to reduce the
model into the rectangular, dotted area shown in Fig. 5. After
reducing the total area to 140 mm 100 mm 60 mm, simu-
lation results show less than 0.5% error in resonance frequency
and 0.1% error in 3-dB bandwidth, while the calculation time is
greatly reduced by about 70%.
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TABLE II
EM SIMULATION AND MEASUREMENT RESULTS, WHEN
THE SENSOR IS ON THE BODY
Fig. 5 shows the simulated normalized E-ﬁeld intensity of 1
V/m as the iso-surface inside each layer of the proposed model.
As can be expected from Table I, the E-ﬁeld experiences more
rapid decay at the skin and muscle layer with its high relative
permittivity due to high water content, while some local expan-
sion of the E-ﬁeld is observed in the fat layer with lower loss
tangent. This provides an important insight in the practical use
that, even if there is a thick layer of fat, the EM ﬁeld will be able
to penetrate well into the skin and fat layer in the abdominal
area. In this model, the E-ﬁeld with an intensity of 1 V/m, for
example, penetrates up to 17.5 mm from the surface of the skin
when the input power is 1 mW. The penetration at each layer
can be calculated by using the deﬁnition of penetration depth in
case of a dielectric with very low conductivity [29],
(2)
where is the real permittivity and is the imaginary permit-
tivity of the dielectric, , and again, is the speed
of light. Table II shows the comparison of simulation and mea-
sured results of the proposed sensor when on the body, proving
that the model is able to predict the measurement with reason-
able accuracy.
C. In Vivo Study—Oral Glucose Tolerance Test
The swept transmission parameter is measured in the
frequency domain by using a vector network analyzer (VNA)
controlled by a PC by using LabVIEW. The software ﬁnds the
peak frequency and 3-dB bandwidth from the initial sweep by
curve ﬁtting a skewed Lorentzian function, then feeding them
back to the instrument to reconﬁgure the measurement span to
two times the 3-dB bandwidth for accurate tracking of property
change. The skewed Lorentzian function is given by (3) [30]
(3)
where is the frequency normalized by itself to lie within
is the linear power transmission through the resonant
sensor, also normalized to lie within . From the six ﬁtted
coefﬁcients – , the resonant frequency is given by
(4)
and the bandwidth by
(5)
Fig. 6. OGTT setup. (a) Schematic diagram and (b) photograph showing the
system connected to the test subject.
For all experiments, the software conﬁgured the VNA to per-
form a segmented sweep with two segments of 101 points over
the bandwidth of two times the 3-dB bandwidth, an IF band-
width of 300 Hz, and source power of 0 dBm. All other set-
tings are as per the defaults for the instrument. The two seg-
ments measured the two resonant modes of the sensor, of which
only the lowest (the “sensing peak” at approximately 1.4 GHz)
is used for analysis.
Fig. 6(a) and (b) shows the experimental setup for an oral glu-
cose tolerance test (OGTT). While the temperature of the alu-
minium shield is monitored by resistance temperature detectors
(RTDs), the temperature inside the shield is monitored and cal-
ibrated by the reference ring technique explained before. For
comparison, measurements of blood glucose are entered with
the microwave data, obtained from a commercial blood strip
device (e.g., Bayer CONTOUR), and also compared with the
data produced by a continuous glucose monitoring device (e.g.,
Medtronic Guardian), worn by the person under test. Our sensor
is attached to the abdominal skin by double-sided adhesive tape
(#1510, Hi-Tack Conformable Double Coated Tape, 3M). To
prevent thermal lag between the rings owing to the low thermal
conductivity of the PTFE support, prior to ﬁxing the sensor on
the body we warm it to approximately 37 C by placing it on
a warm plate for around 15 min. After ﬁxing to the body, the
sensor is left for a further 30 min before readings are taken to
allow it to come into thermal equilibrium with the body.
Two different in vivo test results of the proposed sensor on
a single nondiabetic subject are shown in Figs. 7 and 8. Here
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Fig. 7. OGTT I. The sensor response (here the change in bandwidth) is com-
pared with blood glucose levels measured using a “blood-strip” glucometer
(Bayer CONTOUR).
Fig. 8. OGTT II. Sensor data (change in bandwidth) are measured over a con-
tinuous 12-h period involving three food ingestions, and are compared with data
from a continuous glucose meter (Medtronic Guardian CGM) and blood-strip
glucometer (Bayer CONTOUR), after [27].
we measure the 3-dB bandwidth changes from our sensor that
are temperature corrected using the reference ring.We observe a
change in complex permittivity of the body as a result of glucose
content in the tissue directly beneath the sensor. In vivo tests
were carried out on a single nondiabetic individual. In Fig. 7,
blood strip sensor readings are compared with the proposed mi-
crowave sensor data. Each point (diamond) represents an av-
eraged 3-dB bandwidth from a burst of ten frequency sweep
data. This is repeated three times per blood strip measurement.
Although some variation is observed within the three measure-
ments, the data show good precision in general. Such OGTT
results are often presented in the context of NIBGM, but are
not necessarily indicative of a successful device owing to other
physiological changes that are triggered, e.g., in body tempera-
ture and blood salinity.
The measurements in Fig. 8 cover a period of 12 h with
three separate food intakes (i.e., breakfast, lunch, dinner). Each
point (diamond) represents an average of three 3-dB bandwidth
values, each extracted from a burst of ten frequency sweep
data. In this result, it is notable that the peak immediately after
lunch is not clearly represented by the commercial continuous
glucose monitor (square) or even by the blood strip measure-
ment (circle), while microwave data (diamond) clearly show
a peak at the expected time frame after lunch. Although most
widely used, the accuracy of the glucose meter can be easily
affected by several factors, including calibration, temperature,
quality of blood sample, high levels of interferents, humidity,
and aging of test strips [31].
Fig. 9. 3-D cross-section view of the Franz Cell—sensor assembly.
This provides a far more precise picture than that obtained
from an oral glucose tolerance test because results from dif-
ferent blood glucose episodes can be quantiﬁed next to each
other. Many other techniques attempting to solve the same
problem of noninvasive blood glucose monitoring examine
only one food cycle. In our experience this is not sufﬁcient
to evaluate the effectiveness of the measurement method in
question. Note that the subject is nondiabetic so the blood
glucose levels here are in the very limited range between 4.5 to
7.6 mmol/L (i.e., 80–150 mg/dL).
III. In Vitro INTERFERENCE TEST
A. Measurement Setup
The Franz cell was ﬁrst introduced in 1975 to systematically
validate percutaneous absorption of human skin in vitro [32],
and has become the most widely used method in understanding
the permeation characteristics of synthetic or biological mem-
brane in, for example, transdermal drug delivery [33]. Typically,
a Franz cell consists of two separate chambers, a donor chamber
on the top and receptor chamber on the bottom, with the mem-
brane under test placed horizontally between the two chambers.
The donor chamber is ﬁlled with the material to be permeated
through a test membrane, and the sample is obtained from the
sampling arm in the receptor chamber. For temperature control,
the receptor chamber is surrounded by a temperature jacket with
inﬂow and outﬂow arms, which is ﬁlled with water.
In this experiment, since the goal is to monitor the change
in dielectric properties due to glucose and other interferents in-
jection by using the proposed sensor, some adjustment is made
in the Franz cell assembly. The donor chamber is replaced by
the proposed sensor, and the membrane under test is replaced
by the Perﬂuoroalkoxy copolymer (PFA, Goodfellow) barrier.
The sampling arm is used as a ﬁlling arm to inject glucose and
other interferents. Franz cells with 40-mm receptor oriﬁce di-
ameter and a volume of approximately 21 mL were chosen for
the in vitro experiments, as shown in Fig. 9. The use of the pro-
posed double split-ring sensor is preferable as it makes these ex-
periments more relevant and more readily interpreted by direct
comparison to in vivo studies. Before the experiment measure-
ment, small adjustments have to be made to the double split-ring
sensor. The rings are moved further way from the sample to
match better the conditions of the Franz cell since water has a
higher microwave loss per unit volume than living tissue; hence,
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Fig. 10. Schematic diagram of the measurement setup (resistance temperature
detector: RTD).
the in vivo arrangement would otherwise suffer from excessive
absorption of the EM ﬁeld.
Fig. 10 shows the schematic diagram of the measurement
setup. A primary thermal bath contains the sensors and four
RTDs. The temperature of the thermal bath and of the sensor
housing is continuously monitored using platinum resistance
thermometers in order to ensure stable operating conditions
during the experiment. RTDs 3 and 4 are mounted on a raised
stainless-steel perforated plate mounted in the bottom of the
thermal bath. RTDs 1 and 2 are mounted directly on the sensor
shield. The temperature at each RTD is logged continuously
by the laptop during experiments. The Lab armour beads
completely ﬁll the bath and are poured over the sensors to
completely submerge them before measurement, leaving only
the Franz cell ﬁlling arm exposed. A secondary thermal bath
(not shown) is used to keep all reagents required for injection
into the cells ready at 37 C.
The two sensors are multiplexed using two switches con-
trolled by a digital output of a multifunction I/O unit that is in-
terfaced to the laptop via USB.When the switches are in the ﬁrst
position, the VNA measures Sensor 1, and when in the second
position, the VNA measures Sensor 2. The VNA is set to begin
eachmeasurement on an external trigger signal. This is provided
by an external signal generator set to output square-waves with
a frequency of 1 Hz. Thus, each sensor is measured alternately
every 2 s.
Two split-ring sensors are ﬁtted to two Franz cells so that one
could function as a reference sensor if required (with no added
interferents). The bath is set to 37 C providing a mean sensor
temperature of 34 C. Furthermore, no stirrer bar is used due to
its interference with the microwave sensor, caused by the move-
ment of its high permeability magnet material. A photograph of
an individual sensor and Franz cell arrangement and the pair of
sensors immersed in the thermal bath are shown in Fig. 11.
B. Sample Preparation and Experiment
Initial Franz cell measurements are made using an inert mem-
brane of 1-mm thickness. PFA (Goodfellow) is chosen, as it
has a negligible effect on the chemistry of the cells or on the
Fig. 11. Photograph of the measurement setup. Two sensors are immersed in an
aluminium bead thermal bath. The glucose and interferent solutions are injected
to the exposed sampling arm of one Franz cell.
EM ﬁeld of the sensor. Cells are initially ﬁlled with phosphate
buffered saline (PBS). The PFA layer is sealed using vacuum
grease. The ring sensors are secured to these cells using an ad-
hesive membrane (CoTran 9720 backing, 3M). The loaded cells
are left overnight to thermally equilibrate. Both sets of cells
and sensor are measured simultaneously using an electronic mi-
crowave switch arrangement. One cell is maintained with PBS
solution only to act as a baseline reference where necessary.
A 1-M stock solution of glucose is prepared by dissolving
glucose powder (G7528, Sigma-Aldrich), in high-performance
liquid chromatography (HPLC) grade water (Fisher). Glucose
solution is then spiked into the Franz cells in 200- L aliquots,
up to 600 L, following removal of the same volume of receptor
phase solution. Each injection of concentrated glucose solution
thus increases the glucose concentration in the Franz cell by
approximately 28 mM, based on a cell volume of approximately
21 mL. After each injection, the experiment is left for 30 min to
equilibrate in temperature and concentration.
Due to the prolonged setup time of the cells, it was decided to
combine interferent experiments. Thus, on the assumption that
there is no interaction between interferents (a fair assumption
given that they are normally coexistent in blood), the interferent
and glucose experiments are divided into two separate experi-
ment series that can be run without disassembly. Stock solu-
tions of interferent are produced by dissolving powders (99%,
Sigma-Aldrich) in HPLC grade water. The concentrations of the
various interferents are compounded as the sequence progressed
and the relative changes in sensor readings are taken. The series
shown in Table III are then used as the basis for all subsequent
Franz cell studies.
Due to the high limit of detection of glucose with this par-
ticular experimental setup, caused by a number of factors dis-
cussed in Section III-C, the concentrations used for these exper-
iments are chosen to be much higher than the nominal ranges
found in blood. All microwave sensors of our type will not be
speciﬁc to glucose, so in order to generate meaningful data, the
concentrations of all interferents are extended up to three times
those initially found in the human body. Using a minimum of
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TABLE III
TYPE OF INTERFERENTS AND LIST OF INJECTION
Fig. 12. Change in resonance frequency and change in bandwidth over time
with glucose andmaltose injection, according to experiment series 1 in Table III.
three concentration values allows for any correlation between
sensor response and interferent to be more readily discerned.
Glucose concentration is also extended far beyond the clinical
range so that its effect could be reliably detected before each
experiment. Thus, interferent experiment series 2 is conducted
with a constant glucose concentration of 84mM. To optimize re-
sources it is decided to focus on endogenous interferents only.
C. Results and Discussion
Data for experiment series 1 in Table III are shown in Fig. 12.
The level of noise is two orders of magnitude higher than that
experienced when the Franz cell is empty, indicating that its
origin is due to the presence of the solution in the cell. This
noise occurs because the solutions’ main constituent, water, has
a dramatic effect on the microwave EM ﬁeld, which makes this
experimental setup sensitive to several perturbing factors.
Primary among these is temperature, which causes the per-
mittivity of water to decrease by 1% per C increase in tem-
perature. Although the temperature of the aluminium shield is
continually monitored and typically shows ﬂuctuations of less
than 0.1 over a 30-min period, temperature sensitivity to the
liquid solution is so high that such ﬂuctuations can explain the
large amplitude of the noise seen. This explanation is further re-
inforced by the distribution of the noise spectral energy toward
low frequencies, as would be expected for a thermal systemwith
a large time constant. The low sensitivity to glucose found in
these inert barrier reference experiments compared to that found
in vivo (around 3 kHz/mM here, as opposed to 100 kHz/mM in
vivo) means that this level of noise becomes signiﬁcant. Tem-
perature control with this precision is not an issue in vivo due to
the unexpectedly high responsivity to glucose found in previous
in vivo experiments.
It would be difﬁcult to maintain greater temperature stability
than this in these experiments. Furthermore, due to the con-
ﬁnes of the Franz cell geometry, it is not practical to measure
the temperature of the solution directly. Even if this were pos-
sible, few temperature measurement devices have a sensitivity
as acute and response time as immediate as the microwave res-
onant sensor itself. Thus, temperature correction via thermom-
etry is unhelpful. Another possible solution to temperature cor-
rection is to use the secondary mode of resonance of the double
split-ring resonator as a reference. However, because both reso-
nant sensor modes are in a regime where ﬂuctuations are dom-
inated by the sample itself, any ﬂuctuations due to temperature
are inseparable from those due to concentration of measurand
solute, making temperature correction using reference modes
also unhelpful. Thus, after much effort to reduce the level of
ﬂuctuations to a minimum level, it is decided to proceed and
to increase the concentration of glucose to a resolvable level at
three times that originally planned, and similarly scale the inter-
ferent concentrations in accordance.
The time-domain data of Fig. 12 are re-plotted in Figs. 13 and
14, where we plot directly the change in resonant frequency
and change in bandwidth as a function of glucose and maltose
concentration, respectively. In Fig. 13(a), we note that these
changes are small, approximately 3.287 kHz per mM in reso-
nant frequency. This is smaller by an order of magnitude and
in the opposite direction compared to those measured previ-
ously during in vivo studies of blood glucose using the same sen-
sors (approximately 100 kHz per mM in resonant frequency).
We observe a linear decrease of resonant frequency with in-
creasing glucose concentration, as shown in Fig. 13(a). The
sensor can thus measure glucose linearly based on resonant fre-
quency. However, the noise level is such that the limit of detec-
tion is at least 30 mM when sampling once every second (based
on three times the root mean square noise amplitude of 30 kHz).
The resonant bandwidth, although it shows linear correlation
after 80 mM, is a nonlinear function of glucose concentration
and shows very little variation over clinically important concen-
trations, up to 30 mM. Slope of change due to maltose is even
smaller than due to glucose, showing 1.365 kHz per mM in
resonant frequency, as shown in Fig. 14. However, the in vitro
slope of change in bandwidth is 8.365 kHz per mM, which is
larger than per mM in glucose concentration.
Fig. 15 shows the interferents from experiment series 2 in
Table III measured over time. Data are split over the course of
two days to better observe any long-term effect of earlier injec-
tion (injection 1–10 in experiment series 2). In the change in res-
onance trace, the initial glucose injection is apparent as a large
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Fig. 13. Linear correlation showing sensitivity between: (a) resonance
frequency change and glucose concentration and (b) bandwidth change and
glucose concentration, from experiment series 1.
Fig. 14. Sensitivity of resonance frequency change and bandwidth change over
maltose concentration, from experiment series 1.
initial step in the measurement cell sensor readings. All sub-
sequent interferents appear to have negligible effect on sensor
readings at the concentrations measured. Thus, one can draw a
Fig. 15. Change in resonance frequency and bandwidth over time with glucose
and interferents, according to experiment series 2 in Table III.
provisional conclusion that none of the interferents tested has
any direct and signiﬁcant effect on glucose measurement, even
at concentrations several times that found in blood.
IV. CONCLUSION
In this paper, a noninvasive and continuous blood glucose
monitoring sensor topology based on microwave technology
has been proposed and validated with in vivo and in vitro in-
terference tests. The results compare favorably with commer-
cial invasive blood glucose monitors. It should be stressed that
the test subjects in this work are nondiabetic so only a narrow
range of blood glucose levels are involved here. We next plan
to conduct clinical trials on people with diabetes, which will ex-
tend the range of glucose values to populate fully the consensus
error grid and test more fully the application of our sensor to
this hugely important healthcare problem.
By careful measurements of a sensor adapted to ﬁt a Franz
cell, we have investigated the effects of increasing glucose
concentration on the sensor response and studied the effects of
endogenous interferents common to all subjects, i.e., common
sugars, vitamins (ascorbic acid), and metabolites (uric acid).
With an inverted membrane, we measured the subtle changes
in the water response caused by dissolved species, which give
extremely small sensor responses, even for concentrations well
above those that are clinically relevant. Now we have shown
that maltose, fructose, and galactose also produce only small
changes, at least three times less than the effects of glucose,
and that other endogenous interferents have no signiﬁcant
direct effect. Continued interference studies, including further
exogenous interferers (e.g., pharmaceuticals) will be performed
as part of ongoing work if necessary and of value.
The fact that in vitro glucose measurements produce measur-
able signals at unreasonably high glucose readings (more than
50 mM/L) compared with the in vivo studies is a curiosity of
these microwave measurements that is consistent the observa-
tions of others. We conclude that the in vivo measurement of
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glucose using this microwave technique is not a direct one, and
this merits further investigation as to the mechanism of the glu-
cose modiﬁcation of the dielectric property of human tissue.
REFERENCES
[1] “2014 annual report,” Diabetes UK, London, U.K., 2015.
[2] S.Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalent
of diabetes,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, May 2004.
[3] D. C. Klonoff, “Noninvasive blood glucose monitoring,” Diabetes
Care, vol. 20, no. 3, pp. 433–437, Mar. 1997.
[4] O. S. Khalil, “Spectroscopic and clinical aspects of noninvasive glu-
cose measurements,” Clin. Chem., vol. 45, no. 2, pp. 165–177, Feb.
1999.
[5] S. K. Vashist, “Continuous glucose monitoring systems: A review,”
Diagnostics, vol. 3, no. 4, pp. 385–412, Oct. 2013.
[6] J. Kost, S. Mitragotri, R. A. Gabbay, M. Pishko, and R. Langer, “Trans-
dermal monitoring of glucose and other analytes using ultrasound,”Na-
ture Med., vol. 6, no. 3, pp. 347–350, Mar. 2000.
[7] A. DeHennis et al., “An integrated wireless ﬂuorimeter for a long term
implantable, continuous glucose monitoring system,” presented at the
7th Int. Adv. Technol. Treatments for Diabetes Conf., Vienna, Austria,
Feb. 5–8, 2014.
[8] F. Chowdhury and Y. Han, “Comparative performance between the
former Glucowatch® and an improved non-invasive continuous glu-
cose monitoring watch (CGMWatch™),” presented at the 7th Int. Adv.
Technol. Treatments for Diabetes Conf., Vienna, Austria, Feb. 5–8,
2014.
[9] A. Gal et al., “Calibration schemes of a truly non-invasive glucose
monitor for variety of diabetics,” presented at the 7th Int. Ad. Technol.
Treatments for Diabetes Conf., Vienna, Austria, Feb. 5–8, 2014.
[10] Y. Liao, H. Hao, A. Lingley, B. Parviz, and B. Otis, “A 3-uW CMOS
glucose sensor for wireless contact-lens tear glucose monitoring,”
IEEE J. Solid-State Circuits, vol. 47, no. 1, pp. 335–344, Jan. 2012.
[11] O. Amir et al., “Continuous noninvasive glucose monitoring tech-
nology based on occlusion spectroscopy,” J. Diabetes Sci. Technol.,
vol. 1, no. 4, pp. 463–469, Jul. 2007.
[12] M. Schoemaker, G. Schmelzeisen-Redeker, and J. Jager, “CGM sensor
design principles for reliable and accurate glucose monitoring in the
subcutaneous tissue,” presented at the 7th Int. Adv. Technol. Treat-
ments for Diabetes Conf., Vienna, Austria, Feb. 5–8, 2014.
[13] K. Grenier et al., “Integrated broadband microwave and microﬂuidic
sensor dedicated to bioengineering,” IEEE Trans. Microw. Theory
Techn., vol. 57, no. 12, pp. 3246–3253, Dec. 2009.
[14] B. R. Jean, E. C. Green, and M. J. McClung, “A microwave frequency
sensor for non-invasive blood-glucose measurement,” in IEEE Sensors
Appl. Symp., Atlanta, GA, USA, 2008, pp. 4–7.
[15] M. Hofmann, T. Fersch, R. Weigel, G. Fischer, and D. Kissinger, “A
novel approach to non-invasive blood glucose measurement based on
RF transmission,” inProc. IEEE Int. Med. Meas. Appl. Workshop, Bari,
Italy, May 2011, pp. 39–42.
[16] M. Hofmann, G. Fischer, R. Weigel, and D. Kissinger, “Mi-
crowave-based noninvasive concentration measurements for biomed-
ical applications,” IEEE Trans. Microw. Theory Techn., vol. 61, no. 5,
pp. 2195–2204, May 2013.
[17] T. Yilmaz, R. Foster, and Y. Hao, “Broadband tissue mimicking phan-
toms and a patch resonator for evaluating noninvasive monitoring of
blood glucose levels,” IEEE Trans. Antennas Propag., vol. 62, no. 6,
pp. 3064–3075, Jun. 2014.
[18] P. H. Siegel, Y. Lee, and V. Pikov, “Millimeter-wave non-invasive
monitoring of glucose in anesthetized rats,” in 39th Int. Infrared, Mil-
limeter, Terahertz Waves Conf., Tucson, AZ, USA, Sep. 14–19, 2014,
pp. 1–2.
[19] J. H. Pack, C. S. Kim, B. C. Choi, and K. Y. Ham, “The correlation of
the complex dielectric constant and blood glucose at low frequency,”
Biosens. Bioelectron., vol. 19, no. 4, pp. 321–324, Dec. 2003.
[20] A. Caduff, E. Hirt, Y. Feldman, Z. Ali, and L. Heinemann, “First human
experiments with a novel non-invasive, non-optical continuous glucose
monitoring system,” Biosens. Bioelectron., vol. 19, no. 3, pp. 209–217,
Nov. 2003.
[21] M. Mehdizadeh, T. K. Ishii, J. S. Hyde, and W. Froncisz, “Loop-gap
resonator: A lumpedmodemicrowave resonant structure,” IEEE Trans.
Microw. Theory Techn., vol. MTT-31, no. 12, pp. 1059–1064, Dec.
1983.
[22] I.Wolff and V. K. Tripathi, “Themicrostrip open-ring resonator,” IEEE
Trans. Microw. Theory Techn., vol. MTT-32, no. 1, pp. 102–107, Jan.
1984.
[23] D. J. Rowe et al., “Improved split-ring resonator for microﬂuidic
sensing,” IEEE Trans. Microw. Theory Techn., vol. 62, no. 3, pp.
689–699, Mar. 2014.
[24] A. A. Abduljabar, D. J. Rowe, A. Porch, and D. A. Barrow, “Novel
microwave microﬂuidic sensor using a microstrip split-ring resonator,”
IEEE Trans. Microw. Theory Techn., vol. 62, no. 3, pp. 679–688, Mar.
2014.
[25] D. Slocombe, A. Porch, E. Bustarret, and O. A. Williams, “Microwave
properties of nanodiamond particles,” Appl. Phys. Lett., vol. 102, no.
24, Jun. 2013, Art. ID 2441021.
[26] G. A. Rinard and G. R. Eaton, “Loop-gap resonators,” in Biological
Magnetic Resonance, Biomedical EPR, Part B: Methodology, Instru-
mentation, and Dynamics, S. S. Eaton, G. R. Eaton, and L. J. Berliner,
Eds. New York, NY, USA: Springer, 2005, vol. 24.
[27] H. Choi, J. Naylon, S. Luzio, J. Beutler, and A. Porch, “Design of con-
tinuous non-invasive blood glucose monitoring sensor based on a mi-
crowave split ring resonator,” in RFWireless Technol. Biomed. Health-
care Appl./IEEE MTT-S Int. Microw. Workshop Series, London, U.K.,
Dec. 8–10, 2014, pp. 1–3.
[28] S. Gabriel, R. W. Lau, and C. Gabriel, “The dielectric properties of
biological tissues: II. Measurements in frequency range 10 Hz to 20
GHz,” Phys. Med. Biol., vol. 41, no. 11, pp. 2251–2269, Nov. 1996.
[29] J. Behari, MicrowaveDielectric Bahavor of wet Soils. NewYork, NY,
USA: Springer, 2005.
[30] M. V. Klein, Light Scattering in Solids I, M. Cardona, Ed. Berlin,
Germany: Springer-Verlag, 1983.
[31] B. H. Ginsberg, “Factors affecting blood glucose monitoring: Sources
of errors in measurement,” J. Diabetes Sci. Technol., vol. 3, no. 4, pp.
903–913, Jul. 2009.
[32] T. J. Franz, “Percutaneous absorption. On the relevance of in vitro
data,” J. Investigat. Dermatol., vol. 64, no. 3, pp. 190–195, 1975.
[33] J. J. Kim and K. Park, “Modulated insulin delivery from glucose-sensi-
tive hydrogel dosage forms,” J. Control. Release, vol. 77, no. 1–2, pp.
39–47, Nov. 2001.
Heungjae Choi (S’06–M’11) received the B.S.,
M.S., and Ph.D degrees in electronic engineering
from Chonbuk National University, Jeonju, Korea,
in 2004, 2006, and 2011, respectively.
From 2006 to 2011, he served his alternative
military service as a Specialty Research Worker. He
is currently a Post-Doctoral Research Associate with
the Centre for High Frequency Engineering, Cardiff
University, Cardiff, U.K. From 2011 to 2012, he
was involved with the development of ultra-fast
active harmonic load–pull system development in
collaboration with National Instruments and had two successful live demon-
strations at 2012 European Microwave Week, Amsterdam, The Netherlands,
and 2013 IEEE Radio and Wireless Week, Austin, TX, USA. Since 2013, he
has been involved with the development of the noninvasive blood glucose
monitoring sensor system and clinical trials funded by the Wellcome Trust.
He has authored or coauthored over 50 papers in peer-reviewed journals and
conference proceedings. His research interests include microwave circuits, es-
pecially high-efﬁciency power ampliﬁers and linearizers, and their application
to material characterization and biomedical engineering.
Dr. Choi has served as a reviewer for IEEE MICROWAVE AND WIRELESS
COMPONENTS LETTERS, the IEEE TRANSACTIONS ON CIRCUITS AND
SYSTEMS—II: EXPRESS BRIEFS, Progress in Electromagnetics Research, IET
Microwaves, Antennas and Propagation, and the International Journal of An-
tennas and Propagation. He was the recipient of the Outstanding Achievement
Award of Student High Efﬁciency Power Ampliﬁer Design Competition, 2008
IEEE Microwave Theory and Techniques Society (IEEE MTT-S) International
Microwave Symposium (IMS), and the 2010 Samsung Human Tech Thesis
Prize Award.
Jack Naylon received the M.Eng. degree in elec-
tronic engineering and Ph.D. degree in microwave
resonant sensors from Cardiff University, Wales,
U.K., in 2007 and 2011, respectively.
He is currently Leader of the Laser Controls Sys-
tems Group, ELI Beamlines, Academy of Science,
Institute of Physics, Prague, Czech Republic, where
he develops femtosecond laser control and stabiliza-
tion systems.
CHOI et al.: DESIGN AND In Vitro INTERFERENCE TEST OF MICROWAVE NONINVASIVE BLOOD GLUCOSE MONITORING SENSOR 3025
Steve Luzio is currently a Clinical Scientist and Pro-
fessor of eiabetes with Swansea University, Swansea,
U.K. He possesses over 30 years of experience in
running clinical trials in the ﬁeld of diabetes. He has
coauthored over 150 peer-reviewed publications.
Jan Beutler has been involved with the development
of a noninvasive blood glucose monitoring sensor
system at Cardiff University, Wales, U.K., since
2008. He is currently a Director of the data analytics
company Komiri, Cardiff, U.K.
James Birchall received the B.Pharm degree from
Bath University, Bath, U.K., in 1993, and the Ph.D.
degree (researching drug and DNA delivery systems)
from Cardiff University, Cardiff, U.K., in 1998.
He is currently a Professor of Pharmaceutical
Sciences and Deputy Director of Research and
Engagement with the School of Pharmacy and
Pharmaceutical Sciences, Cardiff University. His
current research is focused on the use of micronee-
dles for cutaneous drug, vaccine, nanoparticle and
gene delivery with activities spanning microneedle
design and fabrication, formulation integration, biological assessment of drug
targeting and response, enduser engagement, and safety and efﬁcacy evaluation
in human subjects. He has been an Associate Editor of Critical Reviews for
Therapeutic Drug Carrier Systems. He is a member of the Editorial Board
of Expert Review of Medical Devices. He is an Honorary Senior Lecturer
and Research Pharmacist with the National Health Service. His research has
been funded by the European Union (EU Commission), National Institutes
of Health (NIH), JDRF, Wellcome Trust, Engineering and Physical Sciences
Research Council (EPSRC), Royal Society, British Skin Foundation, and
various pharmaceutical companies.
Dr. Birchall cofounded the International Conference on Microneedles series.
He has presented invited talks at over 50 international meetings and academic
institutions. He has acted as a temporary advisor to the World Health Organiza-
tion (WHO) on microneedle vaccine technology.
Chris Martin received the M.Pharm and Ph.D. de-
grees in pharmacy and pharmaceutical sciences from
the Cardiff School of Pharmacy and Pharmaceutical
Sciences (CSPPS), Cardiff University, Wales, U.K.,
in 2007 and 2012, respectively.
During his Ph.D. studies, he was engaged in
biodegradable microneedle fabrication and evalu-
ation in vitro. He completed a short Postdoctoral
position with the CSPPS in 2012, which involved
in vitro assessment of a novel noninvasive blood
glucose monitor, prior to beginning a part-time
Research Associate position with St. Mary’s Pharmaceutical Unit, Cardiff and
Vale University Health Board. Alongside this research position, he is currently
with Viridian Pharma Ltd., Newport, U.K., a company engaged in the licensure
of paediatric medicines. His current research interests include advanced oral
dosage forms, particularly for paediatric patients, and topical formulations for
the relief of neuropathic pain conditions.
Adrian Porch received the M.A. degree in physics
and Ph.D. degree in low-temperature physics from
Cambridge University, Cambridge, U.K.
He is currently a Professor with the School of
Engineering, Cardiff University, Cardiff, U.K.,
and a Member of the Centre for High Frequency
Engineering. He is also Deputy Director of the
School of Engineering, Cardiff University, where
he is responsible for research and innovation. He
possesses over 25 years of experience in applying
microwave methods to measure and understand the
fundamental properties of electronic materials. More recently, his techniques
have been used to develop new types of electromagnetic sensors with an
emphasis on applications across different disciplines.
